Novel Derivative of Psilocybin May Provide a More Accessible, Effective Form of Treatment for PTSD
August 23rd 2021Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.
Oncology Reimbursements Must Improve Patient Access, Provide for Overhead Costs
August 20th 2021Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.
Assessing the Recognition of Community Pharmacy’s Role, Policies, Value to Citizens Globally
August 16th 2021Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association, addresses how the role of pharmacists, opportunities, and issues facing community pharmacies internationally compare to the experience of community pharmacists in the United States.
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline
August 16th 2021Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.
Pharmacist Medication Insights: Darzalex Faspro for Multiple Myeloma
August 16th 2021Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.